This combination therapy with CD19-CAR-T cells and allo-HSCT was shown to prolong leukemia-free survival (LFS) with acceptable safety and efficacy compared to CAR-T-cell monotherapy [195,196]. This evidence concerns the gene CD19 and leukemia.